Getting Started
What Qope IsYour First 15 MinutesInterface TourPlans and Access
Drug Intelligence
Drug ProfilePatent CliffShortages TrackerInsightsTerritory Brief
Access & Organizations
MapSafety-Net IntelligenceEHR Vendor Intelligence
Workspace
Lead ListsRadarPins and Saved Views
Databases
Working with TablesRecord PagesExportsDataset Catalog
Account
Plans and BillingUsage and LimitsTeams and MembersProfile and Security
Data & Methodology
SourcesFreshnessData CaveatsGlossary
Support
FAQTroubleshooting
Open the app
Documentation/Drug Intelligence/Patent Cliff

Patent Cliff

Upcoming loss-of-exclusivity events from the Orange Book, scored for how contestable the market actually is.

Open Patent Cliff -- in the sidebar under Drug Intelligence.

A patent expiry is only an opportunity if somebody can act on it. Patent Cliff starts from the FDA Orange Book, works out when each brand's protection actually lapses, and then scores what the market looks like on the far side.

Patent mode and exclusivity mode

A toggle at the top switches the whole page between two clocks:

  • Patent -- when the listed patents expire.
  • Exclusivity -- when the FDA-granted exclusivity gates expire.

They are different dates and often years apart. A drug can be patent-free but still blocked by exclusivity, and vice versa. The market open date is the latest of all gates, and that is the date a generic can actually launch.

Contestability tiers

Every row carries one of four chips, based on how many generic makers are actively marketing the ingredient (not merely holding an approval):

TierMeaning
GreenfieldNo generic actively marketed. First-mover opening.
OpenOnly a few generics actively marketed. Room to enter.
CrowdedSeveral generics actively competing.
ErodedHeavily genericized. Margins likely already compressed.

Hover the chip for the full breakdown: makers actively marketing, makers whose every listing is discontinued (counted separately, not counted as competition), live ANDA listings, whether a Reference Listed Drug is on file, and whether any generic carries an AB therapeutic-equivalence rating. That last one matters: without an AB rating a pharmacist cannot substitute automatically, so brand share erodes far more slowly than the generic count implies.

Other row badges

  • Staged -- tentatively approved generic applications. FDA-cleared, blocked only by patent or exclusivity, positioned to launch the day protection lapses.
  • Discontinued -- every Orange Book listing for this brand is marked DISCN across all years. The protection date still lapses, but it opens an empty market.
  • Brand opens / Blocked to -- this listing's protection lapses on the date shown, but another listing for the same brand runs later. Generic entry stays blocked until that later date.
  • No AB substitute -- generics exist but none are automatically substitutable.

Tabs

Cliff wave

The default view. Loss-of-exclusivity events grouped by year, with per-row contestability, staged-generic counts and Medicare exposure where it can be measured. This is the screening list.

Opened this year

Molecules whose last Orange Book patent and exclusivity gate lapsed earlier this year, then checked against the FDA NDC directory to see what actually reached the market. A gate lapsing and a generic shipping are not the same event, and this tab is where the difference shows.

Biologic cliff

Reference biologics reaching the end of their 12-year BPCIA exclusivity -- the earliest date FDA can license a biosimilar. Sourced from the Purple Book, not the Orange Book, because biologics do not have ANDA generics.

Opportunities

Scored ranking: Medicare exposure multiplied by generic whitespace multiplied by urgency, with measured exposure ranked ahead of estimated. Use this when you want one ordered shortlist rather than a year-by-year view.

Switch targets

Medicare Part D prescribers writing brands whose final patent or exclusivity gate falls in the current or next year. These are the accounts where a generic conversation lands soonest. Exportable as a prospecting list.

Defender

The brand-side view. Each brand losing protection, split by defensive posture -- how much of the portfolio is exposed, what remains protected, and how contested the follow-on market will be. Useful if you are on the originator side rather than the entrant side.

Market-open calendar

The soonest date a generic can actually launch: the latest of all patents and FDA exclusivity gates, resolved per ingredient plus originator rather than per listing. This is the tab to trust for a date you will put in a plan.

Supply-gap openings

Molecules losing protection that are also in an active FDA shortage right now. A supply gap the market cannot currently fill, about to become legally contestable, is the strongest combined signal in the product.

Applicant roll-up

Below the tabs, applicants are ranked by the steepest cliffs -- which companies have the most protection lapsing, weighted by measured Medicare spend where available. Useful for target screening and for competitive briefings.

Known limitations

  • Deduplication happens in the view layer. The Orange Book lists one row per application, strength and patent, so a single brand appears many times. Qope collapses these for display; the underlying table still shows every row.
  • Switch targets and Defender still count expired patents in some roll-ups. Treat their counts as directional and confirm against the Market-open calendar.
  • The Medicare join is partial. The Orange Book has no brand-name filter on the prescribing side, so only a minority of cliff brands can be matched to Medicare dollars. Rows without a match show "--", not zero. See Data Caveats.